Результаты поиска

Recent trends in specialty pharma business model.

The recent rise of specialty pharma is attributed to its flexible, versatile, and open business model while the traditional big pharma is facing a challenging time with patent cliff, generic threat, and low research and development (R&D) productivity. These multinational pharmaceutical companies, facing a difficult time, have been systematically externalizing R&D and some even establish their own corporate venture capital so as to diversify with more shots on goal, with the hope of achieving a higher success rate in their compound pipeline. Biologics and clinical Phase II proof-of-concept (POC

Совпадение в полном тексте источника
… Specialty pharma, by contrast, acquires drugs from academia, research institutions, or other companies, and seeks to commercialize them in new markets. … Externalization of R&D: academia versus specialty pharma Most big pharma have long standing collaborations with academic institutions. …